Hoe verhoudt CSL's PE Ratio zich tot zijn concurrenten?

CSL is good value based on its Price-To-Earnings Ratio (33.8x) compared to the peer average (72.6x).

Hoe verhoudt CSL's PE Ratio zich tot andere bedrijven in de Global Biotechs industrie?

CSL is expensive based on its Price-To-Earnings Ratio (33.8x) compared to the Global Biotechs industry average (26.4x).

Wat is CSL's PE Ratio vergeleken met zijn Fair PE Ratio? Dit is de verwachte PE Ratio, rekening houdend met de verwachte winstgroei van het bedrijf, winstmarges en andere risicofactoren.

CSL is expensive based on its Price-To-Earnings Ratio (33.8x) compared to the estimated Fair Price-To-Earnings Ratio (32.2x).

Wat is de reële prijs van CSL als we kijken naar de toekomstige kasstromen? Voor deze schatting gebruiken we een Discounted Cash Flow-model.

CSL (A$281.62) is trading below our estimate of [[fair value]] (A$404.53)

Wat is de 12-maandsprognose van de analisten en hebben we enig statistisch vertrouwen in het consensuskoersdoel?

Target price is less than 20% higher than the current share price.

CSL (ASX:CSL) - Aandelenkoers, Nieuws & Analyse

CSL Overzicht aandelen

Over het bedrijf

CSL fundamentele analyse
Sneeuwvlok Score
Waardering	3/6
Toekomstige groei	3/6
Prestaties in het verleden	5/6
Financiële gezondheid	4/6
Dividenden	0/6

Beloningen

Trading at 30.4% below our estimate of its fair value

Earnings are forecast to grow 13.08% per year

Earnings grew by 20.4% over the past year

Risicoanalyse

Has a high level of debt

CSL Limited Concurrenten

Telix Pharmaceuticals

ASX:TLX

AU$7.2b

Clinuvel Pharmaceuticals

ASX:CUV

AU$685.8m

Regeneron Pharmaceuticals

NasdaqGS:REGN

US$90.8b

Gilead Sciences

NasdaqGS:GILD

US$111.4b

Prijsgeschiedenis en prestaties

Overzicht van alle hoogtepunten, veranderingen en prijsdalingen voor CSL
Historische aandelenkoersen
Huidige aandelenkoers	AU$281.62
52 Week Hoogtepunt	AU$313.55
52 Week Laag	AU$246.55
Bèta	0.33
11 maand verandering	-2.53%
3 maanden verandering	-6.84%
1 Jaar Verandering	13.46%
33 jaar verandering	-9.77%
5 jaar verandering	4.09%
Verandering sinds IPO	35,102.85%

Recent nieuws en updates

With EPS Growth And More, CSL (ASX:CSL) Makes An Interesting Case

Nov 01

We Think CSL (ASX:CSL) Can Stay On Top Of Its Debt

Oct 05

CSL (ASX:CSL) Gains Approval for Updated COVID-19 Vaccine in Japan, Boosting Strategic Alliances

Sep 18

Recent updates

With EPS Growth And More, CSL (ASX:CSL) Makes An Interesting Case

Nov 01

We Think CSL (ASX:CSL) Can Stay On Top Of Its Debt

Oct 05

CSL (ASX:CSL) Gains Approval for Updated COVID-19 Vaccine in Japan, Boosting Strategic Alliances

Sep 18

Getting In Cheap On CSL Limited (ASX:CSL) Is Unlikely

Sep 03

CSL Limited (ASX:CSL) Just Reported Yearly Earnings: Have Analysts Changed Their Mind On The Stock?

Aug 16

An Intrinsic Calculation For CSL Limited (ASX:CSL) Suggests It's 27% Undervalued

Aug 07

CSL Limited's (ASX:CSL) Price Is Out Of Tune With Earnings

May 22

An Intrinsic Calculation For CSL Limited (ASX:CSL) Suggests It's 20% Undervalued

May 01

CSL Limited's (ASX:CSL) Intrinsic Value Is Potentially 47% Above Its Share Price

Aug 13

CSL (ASX:CSL) Has A Pretty Healthy Balance Sheet

May 30

A Look At The Intrinsic Value Of CSL Limited (ASX:CSL)

May 09

Does CSL (ASX:CSL) Have A Healthy Balance Sheet?

Mar 01

Estimating The Fair Value Of CSL Limited (ASX:CSL)

Feb 07

CSL (ASX:CSL) Seems To Use Debt Quite Sensibly

Nov 17

CSL Limited (ASX:CSL) Shares Could Be 24% Below Their Intrinsic Value Estimate

Oct 27

We Think CSL (ASX:CSL) Can Stay On Top Of Its Debt

Aug 19

Is CSL Limited (ASX:CSL) Trading At A 22% Discount?

Jul 29

CSL's (ASX:CSL) Problems Go Beyond Weak Profit

Feb 22

Is CSL Limited (ASX:CSL) Worth AU$270 Based On Its Intrinsic Value?

Jan 19

Rendement voor aandeelhouders

	CSL	AU Biotechs	AU Markt
7D	-3.6%	-3.7%	-1.1%
1Y	13.5%	19.0%	16.1%

Rendement versus industrie: CSL underperformed the Australian Biotechs industry which returned 19% over the past year.

Rendement versus markt: CSL underperformed the Australian Market which returned 16.1% over the past year.

Prijsvolatiliteit

Is CSL's price volatile compared to industry and market?
CSL volatility
CSL Average Weekly Movement	2.3%
Biotechs Industry Average Movement	10.4%
Market Average Movement	8.6%
10% most volatile stocks in AU Market	17.5%
10% least volatile stocks in AU Market	3.6%

Stabiele aandelenkoers: CSL has not had significant price volatility in the past 3 months compared to the Australian market.

Volatiliteit in de loop van de tijd: CSL's weekly volatility (2%) has been stable over the past year.

Over het bedrijf

Opgericht	Werknemers	CEO	Website
1916	32,698	Paul McKenzie	www.csl.com.au

CSL Limited onderzoekt, ontwikkelt, produceert, verkoopt en distribueert biofarmaceutische producten en vaccins in Australië, de Verenigde Staten, Duitsland, het Verenigd Koninkrijk, Zwitserland, China en Hong Kong. Het bedrijf is actief via de segmenten CSL Behring, CSL Seqirus en CSL Vifor. Het CSL Behring segment biedt plasmaproducten, gentherapieën en recombinanten.

CSL Limited Samenvatting

Hoe verhouden de winst en inkomsten van CSL zich tot de beurswaarde?
CSL fundamentele statistieken
Marktkapitalisatie	AU$136.36b
Inkomsten(TTM)	AU$4.03b
Inkomsten(TTM)	AU$22.58b

33.8x

Koers/Winstverhouding

6.0x

P/S-verhouding

Is CSL overgewaardeerd?

Zie Reële waarde en waarderingsanalyse

Inkomsten en omzet

Belangrijkste winstgevendheidsstatistieken uit het laatste winstverslag (TTM)
CSL resultatenrekening (TTM)
Inkomsten	US$14.80b
Kosten van inkomsten	US$7.10b
Brutowinst	US$7.71b
Overige uitgaven	US$5.06b
Inkomsten	US$2.64b

Laatst gerapporteerde inkomsten

Jun 30, 2024

Volgende inkomensdatum

Feb 10, 2025

Winst per aandeel (EPS)	5.46
Brutomarge	52.06%
Nettowinstmarge	17.85%
Schuld/Eigen Vermogen Verhouding	54.2%

Hoe presteerde CSL op de lange termijn?

Bekijk historische prestaties en vergelijking

Dividenden

1.4%

Huidig dividendrendement

48%

Uitbetalingsratio

CSL Overzicht aandelen

Beloningen

Risicoanalyse

CSL Limited Concurrenten

ASX:TLX

AU$7.2b

ASX:CUV

AU$685.8m

NasdaqGS:REGN

US$90.8b

NasdaqGS:GILD

US$111.4b

Prijsgeschiedenis en prestaties

Recent nieuws en updates

With EPS Growth And More, CSL (ASX:CSL) Makes An Interesting Case

CSL Vifor and Travere Therapeutics Announces Swissmedic Approval of FILSPARI (Sparsentan) for the Treatment of IgA Nephropathy

We Think CSL (ASX:CSL) Can Stay On Top Of Its Debt

CSL (ASX:CSL) Gains Approval for Updated COVID-19 Vaccine in Japan, Boosting Strategic Alliances

Japan's Ministry of Health, Labor and Welfare Approves CSL and Arcturus Therapeutics Holdings Inc.'s Updated Self-Amplifying mRNA Covid-19 Vaccine for Protection Against JN.1 Strain

MD, CEO & Executive Director exercised options and sold AU$1.1m worth of stock

Recent updates

With EPS Growth And More, CSL (ASX:CSL) Makes An Interesting Case

CSL Vifor and Travere Therapeutics Announces Swissmedic Approval of FILSPARI (Sparsentan) for the Treatment of IgA Nephropathy

We Think CSL (ASX:CSL) Can Stay On Top Of Its Debt

CSL (ASX:CSL) Gains Approval for Updated COVID-19 Vaccine in Japan, Boosting Strategic Alliances

Japan's Ministry of Health, Labor and Welfare Approves CSL and Arcturus Therapeutics Holdings Inc.'s Updated Self-Amplifying mRNA Covid-19 Vaccine for Protection Against JN.1 Strain

MD, CEO & Executive Director exercised options and sold AU$1.1m worth of stock

Getting In Cheap On CSL Limited (ASX:CSL) Is Unlikely

Upcoming dividend of US$1.45 per share

CSL Limited (ASX:CSL) Just Reported Yearly Earnings: Have Analysts Changed Their Mind On The Stock?

Final dividend of US$1.45 announced

Full year 2024 earnings: EPS misses analyst expectations

CSL Limited to Report First Half, 2025 Results on Feb 11, 2025

An Intrinsic Calculation For CSL Limited (ASX:CSL) Suggests It's 27% Undervalued

Nature Communications Publishes Pivotal Data Demonstrating Efficacy and Tolerability of CSL and Arcturus Therapeutics' COVID-19 Vaccine

CSL Limited's (ASX:CSL) Price Is Out Of Tune With Earnings

An Intrinsic Calculation For CSL Limited (ASX:CSL) Suggests It's 20% Undervalued

Now 21% undervalued after recent price drop

CSL Vifor and Travere Therapeutics Announces European Commission Approves FILSPARI® (sparsentan) for the Treatment of IgA Nephropathy

Does CSL (ASX:CSL) Have A Healthy Balance Sheet?

Now 20% undervalued

CSL Seqirus Confirms Full Preparation to Implement the Fda's Vaccines and Related Biological Products Advisory Committee

Upcoming dividend of US$1.19 per share

First half dividend of US$1.19 announced

First half 2024 earnings: EPS misses analyst expectations

CSL Limited Announces Estimate Distribution for the Six Months Ended December 31, 2023, Payable on April 3, 2024

CSL Announces Top-Line Results from the Phase 3 AEGIS-II Trial Evaluating the Efficacy and Safety of CSL112 (apolipoprotein A-I (Human)

Now 22% undervalued

CSL Limited's (ASX:CSL) Earnings Haven't Escaped The Attention Of Investors

Now 21% undervalued

CSL and Arcturus Therapeutics' ARCT-154 Demonstrates Non-Inferiority to Original Strain and Superior Immunogenicity to Omicronba BA.4/5 Variant Compared to First-Generation mRNA Vaccine Booster Booster

CSL Limited to Report Fiscal Year 2024 Results on Jul 30, 2024

CSL Behring's HEMGENIX (Etranacogene Dezaparvovec-Drlb) Demonstrates At Three Years Post-T Treatment Long-Term Durability, Safety and Greater Bleed Protection Versus Prophylactic Treatment in People Living with Hemophilia B

Is CSL (ASX:CSL) Using Too Much Debt?

Japan's Ministry of Health, Labour and Welfare Approves CSL and Arcturus Therapeutics' ARCT-154, the First Self-Amplifying mRNA Vaccine Approves for COVID in Adults

CSL Limited (ASX:CSL) Shares Could Be 28% Below Their Intrinsic Value Estimate

Health Canada Authorizes Csl's Hemgenix(R) (Etranacogene Dezaparvovec) as First Gene Therapy for Hemophilia B

CSL Limited Reaffirms Financial Outlook for Fiscal Year 2024

CSL Seqirus Announces Data from Three Studies Supporting the Clinical, Public Health Benefit and Cost Savings Associated with Cell-Based and Adjuvanted Influenza Vaccines

CSL Seqirus Shares Data Demonstrating the Potential for Influenza Vaccination to Reduce the Burden on Healthcare Resources

These 4 Measures Indicate That CSL (ASX:CSL) Is Using Debt Reasonably Well

Arcturus Therapeutics Holdings Inc. and Csl Seqirus Announce European Medicines Agency Validates Marketing Authorization Application for Arct-154 Vaccine to Prevent Covid-19

Upcoming dividend of US$1.29 per share at 1.4% yield

Independent Non-Executive Chairman recently sold AU$5.6m worth of stock

CSL Appoints Jeffrey Ball as First Chief Sustainability Officer

CSL Limited, Annual General Meeting, Oct 09, 2024

Full year 2023 earnings: EPS misses analyst expectations

CSL Limited's (ASX:CSL) Intrinsic Value Is Potentially 47% Above Its Share Price

CSL Limited to Report Fiscal Year 2023 Results on Aug 15, 2023

CSL (ASX:CSL) Has A Pretty Healthy Balance Sheet

A Look At The Intrinsic Value Of CSL Limited (ASX:CSL)

Upcoming dividend of US$1.07 per share at 1.1% yield

Does CSL (ASX:CSL) Have A Healthy Balance Sheet?

First half 2023 earnings released: EPS: US$3.37 (vs US$3.85 in 1H 2022)

CSL Limited Announces Interim Dividend, Payable on 5 April 2023

Estimating The Fair Value Of CSL Limited (ASX:CSL)

CSL Limited, Annual General Meeting, Oct 11, 2023

CSL Limited to Report First Half, 2023 Results on Feb 14, 2023

SAB Biotherapeutics Novel DiversitAb™ Platform Proven to Develop Anti-idiotype Antibodies to Help Treat Autoimmune Diseases

CSL Limited Announces Management Changes